WARNING: This product is for research use only, not for human or veterinary use.
Hodoodo CAT#: H530204
CAS#: 311770-26-0
Description: KRP-101 is a PPARɑ agonist potentially for the treatment of diabetes and hyperlipidaemia.
Hodoodo Cat#: H530204
Name: KRP-101
CAS#: 311770-26-0
Chemical Formula: C26H26FNO5
Exact Mass: 451.18
Molecular Weight: 451.494
Elemental Analysis: C, 69.17; H, 5.80; F, 4.21; N, 3.10; O, 17.72
This product is not in stock, which may be available by custom synthesis.
For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge).
Quote less than 1g will not be provided. To request quote, please email to sales @hodoodo.com or click below button.
Note: Price will be listed if it is available in the future.
Synonym: KRP-101; KRP 101; KRP101.
IUPAC/Chemical Name: (S)-2-(3-((4-(4-fluorophenoxy)phenyl)(methyl)carbamoyl)-4-methoxybenzyl)butanoic acid
InChi Key: GXURPXBUGUEVOP-SFHVURJKSA-N
InChi Code: InChI=1S/C26H26FNO5/c1-4-18(26(30)31)15-17-5-14-24(32-3)23(16-17)25(29)28(2)20-8-12-22(13-9-20)33-21-10-6-19(27)7-11-21/h5-14,16,18H,4,15H2,1-3H3,(H,30,31)/t18-/m0/s1
SMILES Code: CC[C@@H](CC1=CC=C(OC)C(C(N(C2=CC=C(OC3=CC=C(F)C=C3)C=C2)C)=O)=C1)C(O)=O
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO
Shelf Life: >2 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
More Info:
Biological target: | |
In vitro activity: | |
In vivo activity: |
The following data is based on the product molecular weight 451.49 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
---|---|---|---|
1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
Formulation protocol: | |
In vitro protocol: | |
In vivo protocol: |
1: Nagasawa M, Hara T, Kashino A, Akasaka Y, Ide T, Murakami K. Identification of a functional peroxisome proliferator-activated receptor (PPAR) response element (PPRE) in the human apolipoprotein A-IV gene. Biochem Pharmacol. 2009 Sep 1;78(5):523-30. doi: 10.1016/j.bcp.2009.05.007. PubMed PMID: 19433068.
2: Tsunoda M, Kobayashi N, Ide T, Utsumi M, Nagasawa M, Murakami K. A novel PPARalpha agonist ameliorates insulin resistance in dogs fed a high-fat diet. Am J Physiol Endocrinol Metab. 2008 May;294(5):E833-40. doi: 10.1152/ajpendo.00627.2007. PubMed PMID: 18212024.
3: Nagasawa M, Akasaka Y, Ide T, Hara T, Kobayashi N, Utsumi M, Murakami K. Highly sensitive upregulation of apolipoprotein A-IV by peroxisome proliferator-activated receptor alpha (PPARalpha) agonist in human hepatoma cells. Biochem Pharmacol. 2007 Dec 15;74(12):1738-46. PubMed PMID: 17904533.